K-RAS-activating mutations occur frequently in non-small cell lung cancer, leading to aberrant activation of the Ras-MAPK signaling pathway that contributes to the malignant phenotype. However, the development of Ras-targeted therapeutics remains challenging. Here, we show that MED23, a component of the multisubunit Mediator complex that is known to integrate signaling and gene activities, is selectively important for Ras-active lung cancer. By screening a large panel of human lung cancer cell lines with or without a Ras mutation, we found that Med23 RNAi specifically inhibits the proliferation and tumorigenicity of lung cancer cells with hyperactive Ras activity. Med23 deficiency in fibroblasts selectively inhibited the oncogenic transformation induced by Ras but not by c-Myc. The transcription factor ELK1, which is phosphorylated by MAPK for relaying Ras signaling to MED23, also was required for the Ras-driven oncogenesis. Transcriptome analysis revealed that MED23 and ELK1 co-regulate a common set of target genes enriched in regulating cellcycle and -proliferation functions to support the Ras dependency. Furthermore, MED23 was up-regulated by Ras transformation in correlation with the strength of Ras signaling as indicated by the ELK1 phosphorylation level and was found to be overexpressed in both Ras-mutated lung cancer cell lines and primary tumor samples. Remarkably, lower Med23 expression predicted better survival in Rasactive lung cancer patients and xenograft mice. Collectively, our findings demonstrate a critical role for MED23 in enabling the "Ras-addiction" of lung carcinogenesis, thus providing a vulnerable target for the treatment of Ras-active lung cancer.
K-RAS-activating mutations occur frequently in non-small cell lung cancer, leading to aberrant activation of the Ras-MAPK signaling pathway that contributes to the malignant phenotype. However, the development of Ras-targeted therapeutics remains challenging. Here, we show that MED23, a component of the multisubunit Mediator complex that is known to integrate signaling and gene activities, is selectively important for Ras-active lung cancer. By screening a large panel of human lung cancer cell lines with or without a Ras mutation, we found that Med23 RNAi specifically inhibits the proliferation and tumorigenicity of lung cancer cells with hyperactive Ras activity. Med23 deficiency in fibroblasts selectively inhibited the oncogenic transformation induced by Ras but not by c-Myc. The transcription factor ELK1, which is phosphorylated by MAPK for relaying Ras signaling to MED23, also was required for the Ras-driven oncogenesis. Transcriptome analysis revealed that MED23 and ELK1 co-regulate a common set of target genes enriched in regulating cellcycle and -proliferation functions to support the Ras dependency. Furthermore, MED23 was up-regulated by Ras transformation in correlation with the strength of Ras signaling as indicated by the ELK1 phosphorylation level and was found to be overexpressed in both Ras-mutated lung cancer cell lines and primary tumor samples. Remarkably, lower Med23 expression predicted better survival in Rasactive lung cancer patients and xenograft mice. Collectively, our findings demonstrate a critical role for MED23 in enabling the "Ras-addiction" of lung carcinogenesis, thus providing a vulnerable target for the treatment of Ras-active lung cancer.
oncogene addiction | transcription cofactor | therapeutic target L ung cancer is the most common form of cancer globally, with an estimated 1.2 million new cases each year. It is also the leading cause of cancer-related mortality worldwide, with a median survival time of 8-11 mo and a 5-y survival rate of 15% (1) . The high mortality rate of this disease results primarily from the diagnosis of the majority of lung cancers at advanced stages when the standard treatment options, such as traditional cytotoxic chemotherapy, are mostly palliative and confer only a limited survival benefit (2) . Therefore, a better understanding of the molecular origins and evolution of lung cancer is needed to develop novel treatment strategies.
As with most cancers, lung cancer arises as a consequence of the accumulation of multiple oncogenic lesions. A point mutation in the K-Ras gene and aberrant Ras-MAPK pathway functioning are early events that contribute to the malignant phenotype of some types of lung cancer (3) . Ras gene family members are mutated in ∼30% of human tumors, and oncogenic mutations in the K-Ras gene are present in ∼35% of non-small cell lung cancers (NSCLCs) (4, 5) . Despite its prominent status as an attractive drug target, development of therapeutics aimed at disrupting the active-Ras function has proven challenging thus far (6, 7) . One obstacle to the development of specific Ras inhibitors is the tendency of mutated RAS proteins to gain constitutive activity, having lost their normal enzymatic function of switching between the active, GTP-bound state and the inactive, GDP-bound state (8) . Such loss-of-function enzymes are much more difficult to inhibit than gain-of-function activated enzymes, such as those produced by EGFR mutations. Moreover, K-Ras mutations have been shown to confer primary or de novo resistance to EGFR-targeted therapies (9) . Although therapeutics targeting the downstream effector molecules of Ras, such as Raf, MEK, and PI3K/mTOR, have proven efficacious in treating tumors with Ras mutations, acquired drug resistance invariably evolves during the treatment (10) (11) (12) (13) . Consequently, the need to identify additional, pharmacologically tractable components for K-Ras-driven tumorigenesis remains pressing.
The Mediator complex is a multisubunit coactivator complex that is evolutionarily conserved from yeast to mammal and that can act as a molecular bridge between gene-specific transactivators and the RNA polymerase II-associated basal transcription machinery (14, 15) . Through physical interactions between the various transcription factors and specific Mediator subunits, the Mediator complex functions as an integrative hub for channeling different signaling pathways (16) , such as the nuclear hormone receptor pathway (via MED1) (17) , the TGF-β-signaling pathway (via MED15) (18) , the Wnt-signaling pathway (via MED12) (19) , and the Ras-MAPK signaling pathway (via MED23) (20, 21) . Emerging studies are beginning to focus on the specificity of Mediator in regulating diverse biological processes, including differentiation, proliferation, metabolism, and carcinogenesis.
Mediator subunit MED23 (Sur2) was identified originally as a genetic regulator of hyperactive Ras in Caenorhabditis elegans. The loss of Med23 could block abnormal vulval development, the phenotype exhibited in response to activated Ras (22) . Considering MED23 as a downstream regulator for the Ras-MAPK signaling pathway, we investigated the function of MED23 in Ras-active lung cancer and explored whether it could be used for clinical diagnosis and target in lung cancer therapy. We found that MED23 and its binding partner Ets-like protein-1 (ELK1) are the critical regulators of "Ras-addicted" lung cancer. Moreover, the expression level of MED23 is correlated with the level of Ras or MAPK activity in human lung cancers and is associated with the prognoses of patients who have Ras-active lung cancer. These findings demonstrate a selective role for MED23 in supporting Ras addiction and Ras-active lung cancer and suggest that MED23 might be a therapeutic target in Ras-active lung cancer.
shRNA to knock down Med23 expression in A549, an NSCLC cell line that harbors a mutated K-Ras gene. Three different shRNAs effectively attenuated the expression of MED23 in A549 cells as indicated by the immunoblotting results, whereas a negative control shRNA did not affect the MED23 expression (Fig. 1A) .
We first investigated whether MED23 is involved in growth control. Equal numbers of WT A549 cells, cells expressing a control shRNA (si-Ctrl), and cells expressing an shRNA against Med23 (si-Med23) were cultured for 6 d. As shown in Fig. 1B , Med23 knockdown decreased the proliferation of all of the siMed23 cells compared with the parental cells and the control shRNA cells. To exclude the off-target effects of the shRNA, the mouse Med23 gene, which is resistant to the shRNA specific for the human Med23, was reintroduced into the si-Med23 A549 cell lines using retroviral transduction (Fig. S1A) . Cells with the incorporated gene were selected with hygromycin. The cell-proliferation assay revealed that ectopic expression of mouse Med23 can rescue the growth defect of the si-Med23 A549 cells (Fig.  S1B ). These data showed that the shRNA's effect is on target. We next investigated whether MED23 participates in anchorage-independent growth and tumorigenesis of A549 cells. Using a soft agar colony-formation assay, we found that the loss of MED23 impaired A549 colony formation in a semisolid medium, and the quantitation of the colonies revealed that Med23 knockdown not only reduced the colony size but also decreased the number of colonies ( Fig. 1C and Fig. S1 E and F). To confirm these observations in vivo, equal numbers of si-Ctrl or si-Med23 A549 cells were implanted s.c. into athymic nude mice. After 7 wk, mice injected with the si-Med23 cells showed smaller tumor masses and volumes than mice injected with si-Ctrl cells (Fig. 1D ). These findings suggest that MED23 plays an important role in tumorigenicity, because the depletion of Med23 inhibited the proliferation and tumorigenicity of A549 cells. Through FACS analysis, we also checked whether Med23 depletion causes increased apoptosis. We observed no increase in annexin V-positive staining cells after Med23 knockdown (using cisplatin-treated si-Ctrl cells as a positive control), suggesting that Med23 knockdown does not induce cell death (Fig. S2) . Thus, the decrease in lung cancer cell numbers and tumorigenicity is the result of the change of the proliferation rate by Med23 knockdown.
We then expanded our screening survey to a larger panel of human lung cancer cell lines with or without a Ras mutation to explore further the phenomenon of Med23 dependency in growth control. The Ras-mutation status of the various cancer cells used in this study was verified using the COSMIC database, and the Ras dependency of these cells was determined previously using high-throughput RNAi (23, 24) . Remarkably, the depletion of Med23 selectively inhibited the proliferation of the cells with mutated Ras, such as H1299, HTB-177, and CRL-5807 (Fig. 1E) ; in contrast, the Med23 knockdown did not appear to affect the growth of the cells with WT Ras, such as HTB-182, H522, and CRL-5889 (Fig. 1F) . Similar results using these lung cancer cells with or without the Ras mutation were observed for the processes of anchorage-independent growth and tumor formation in nude mice (Fig. S3A) . These results suggest a close relationship between the presence of an activated Ras mutation and the requirement for MED23 to control the growth of lung cancer cells.
To test the idea that the Ras-active mutation indeed couples with MED23-dependent growth control, we introduced the oncogenic HRasV12 allele into two lung cancer cell lines with WT Ras, HTB-182, and H522 via retroviral transduction. Notably, after expressing the oncogenic Ras, both cell lines, which previously were resistant to Med23 depletion, displayed dependence on MED23 to some extent; i.e., their growth rates became partially inhibited by Med23 depletion (Fig. S3B) . This result further supported the idea that MED23 plays an important role in the controlling the growth of the lung cancer cells in a Ras activitydependent manner. To test the applicability of the correlation between Ras-mutation status and sensitivity to Med23 depletion to other types of cancer, we investigated the effects of Med23 depletion in different epithelial cancer cell lines. Consistent with our observations in the lung cancer cell lines, the depletion of Med23 impaired the growth of Ras-active pancreatic cancer PANC-1 cells, but not prostate cancer DU145cells that carry a WT Ras ( Fig. 1 E and F) . Taking these results together, we found that, in general, the growth of Ras-active cancer cells is more sensitive to MED23 deficiency than cancer cell lines with WT Ras. These observations strongly suggest that MED23 is selectively required for the growth of Ras-active cancer cells.
MED23 Is Required for Ras-but Not Myc-Induced Cell Transformation.
Because MED23 was found to be important for the proliferation and tumorigenesis of Ras-active cancer cells, we next attempted to establish the functional relationship between MED23 and Ras during oncogenesis. Active Ras is known to be a robust oncogene in inducing malignant transformation (4). We asked whether MED23 is required in Ras-induced transformation. The expression of Ras alone in primary mouse embryonic fibroblasts (MEFs) induces a senescence-like arrest of growth (25, 26) . However, immortalized MEFs defective in the p53 or Rb tumor suppressor pathway can be transformed by a hyperactive Ras mutant, resulting in anchorage-independent growth and tumor formation in nude mice (27, 28) . Hyperactive HRasV12 was overexpressed in WT and Med23 −/− -immortalized MEFs through viral transduction ( Fig. 2A) . The HRasV12 expression in WT MEFs induced anchorage-independent colony growth and tumor formation in the immunodeficient mice; however, Ras transformation was much less efficient in the KO (Med23 −/− ) MEFs than in the WT MEFs ( Fig. 2 B-D) . These observations confirmed that MED23 is critical for Ras to induce transformation and corroborated the role of MED23 in Ras-dependent cancer.
To determine the specific role of MED23 in Ras transformation, we performed a transformation assay using another oncogene, cmyc. Interestingly, Myc transformation appears to be independent of MED23. Unlike Ras transformation, the presence or absence of MED23 did not affect the efficiency of Myc transformation in terms of the size or number of anchorage-independent colonies in a soft agar colony-formation assay ( Fig. 2 E and F) . These data indicate that there is a selective requirement for MED23 during Ras transformation and further support the codependency of active Ras and MED23 in Ras-driven oncogenesis.
ELK1 Controls Tumorigenicity of Lung Cancer Cells and Ras
Transformation. ELK1 is a member of the ternary complex factor family (29) . Upon activation by MAPK, phosphorylated ELK1 (p-ELK1) interacts with the Mediator complex via the MED23 subunit to stimulate the expression of downstream target genes (21, 30, 31) . Therefore, ELK1 could be considered as being genetically upstream of MED23. Because the MED23 seems to control specifically the growth of tumor with activated Ras, we next asked whether ELK1 also can control the process of transformation and the tumorigenicity of lung cancer cells in a Ras-specific manner.
Three different Elk1-specific shRNAs were expressed stably in A549 cells. Attenuated proliferation rates and tumorigenicity were observed, as indicated by the decreased numbers of cells and soft agar colonies compared with those of the control cells (Fig. 3  A-C) . Interestingly, similar to the effect of Med23 knockdown, Elk1 knockdown did not affect the growth of the lung cancer cells with WT Ras, including H522 and HTB-182 cells (Fig. S4 A and  B) . We also performed the Ras-transformation assay in the immortalized MEFs with or without Elk1 depletion and found that the Elk1 RNAi also can decrease the efficiency of Ras transformation (Fig. 3 D-F) . These results suggest that Elk1 seems to phenocopy Med23 in regulating tumorigenicity and that the functional interaction between MED23 and ELK1 might be responsible for the observed Ras-driven oncogenicity.
MED23 and ELK1 Coregulate a Set of Genes Related to Proliferation and Cell-Cycle Functions. Given that MED23 controls the highly specialized active Ras-MAPK signaling by interacting with ELK1, we asked whether MED23 regulates the expression of ELK1 target genes in Ras-active lung cancer cells. Because most ELK1 target genes, such as Egr1, Egr2, Ier2, and c-fos, are immediate early genes (32), we first performed a time course of serum stimulation to examine their expression patterns. The loss of MED23 greatly reduced the expression of all of the examined ELK1 target genes following serum stimulation (Fig. 4A) . Moreover, the expression of the compromised ELK1 target genes in si-Med23 A549 cells could be rescued by reintroducing mouse Med23 cDNA, which is resistant to the human shRNA ( Fig. S1 C and D). Because we had observed that the control of the growth of lung cancer cells by MED23 was dependent on active Ras mutation, we then explored whether MED23 can affect ELK1-targeted gene expression in a Ras-dependent fashion. Strikingly, down-regulation of ELK1 target genes caused by the loss of MED23 occurred only in Ras-active lung cancer cells and not in Ras WT lung cancer cells (Fig. 4B) . Therefore, we concluded that the control of Ras/MAPK/ELK1 downstream gene expression by MED23 is also dependent on active Ras mutation. These data suggest that MED23 is an important cofactor for ELK1-targeted gene expression in Ras-active lung cancer cells.
To gain a genome-wide understanding of how MED23 and ELK1 control gene expression in Ras-active lung cancer cells, we performed gene-profiling experiments to analyze the transcriptomes from control, si-Med23, or si-Elk1 A549 cells. First, we identified the genes that were expressed differentially after the knockdown of Med23 (P < 0.05) and ranked them based on the fold changes of their expression levels. Then, we analyzed whether the knockdown of Elk1 produced a similar effect on these genes. Strikingly, we observed that the loss of ELK1 produced a gene-expression pattern highly similar to that of the Med23 knockdown, with a correlation coefficient of 0.928 (Fig.  4C) . Next, to analyze the functions of the overlapping genes that are controlled by both ELK1 and MED23, a cluster of genes with a fold change in expression of log 2 > 0.5 relative to the control cells was chosen for further analysis. A heat map of these genes shows analogous changes in gene expression following Elk1 or Med23 knockdown (Fig. 4D) , revealing a substantial overlap between the ELK1 and MED23 target genes. Specifically, nearly 57% of all of the genes with expression changes of 1.5-fold or greater in the Elk1 shRNA-treated cells overlapped with those in the Med23 shRNA-treated cells. A Gene Ontology (GO) analysis of the positive overlapping genes, which were down-regulated by the knockdown of either Med23 or Elk1, revealed that cell-cycle and cell-proliferation functions ranked at the top. The expression patterns of the genes selected based on the microarray results were confirmed using quantitative PCR analysis ( Fig. 4 E and F) .
In view of the GO analysis and the decreased proliferation of Ras-active lung cancer cells following Med23 knockdown, we investigated whether Med23 depletion impacts the cell-cycle progression. After cell-cycle synchronization of A549 cells, we observed that the loss of MED23 caused a significant delay in the G2-M transition (Fig. S5B) , as is consistent with the reduction in cell numbers shown by the proliferation assay. Thus, the genome-wide analysis suggested that MED23 controls most of the ELK1-regulated genes in Ras-active lung cancer cells and that both MED23 and ELK1 control a common set of genes related to cell proliferation and cell-cycle regulation.
Finally, to determine whether alterations in upstream signaling led to cell-cycle changes, we investigated whether Med23 deficiency affects Ras signaling transduction. The levels of phosphorylated AKT (p-AKT) and phosphorylated ERK (p-ERK) were examined as readouts of the prominent PI3K and Raf/MEK/ ERK pathways, respectively, downstream of Ras. However, the phosphorylation of neither ERK nor AKT was changed by the Med23 knockdown (Fig. S5A ). Taken together, these results suggest that transcriptome changes may be mainly responsible for the effects of Med23 or Elk1 depletion on growth and proliferation in the Ras-active cancer cells.
MED23 Expression Correlates with Ras-MAPK Signaling Strength in
Human Lung Cancers. The requirement for MED23 during Ras transformation implies a possible oncogenic role for Med23 in Ras-dependent cancers. To understand better the function of MED23 in Ras-active lung cancer, we examined the MED23 expression in 12 human lung cell lines, including two normal human embryonic lung fibroblast lines, two immortalized normal human lung epithelial cell lines, six lung cancer cell lines with mutated Ras, and two lung cancer cell lines with WT Ras. In general, the expression of MED23 was higher in the lung cancer cells than in the normal cells. Notably, the cancer cell lines with mutated Ras expressed more MED23 and ELK1 than the cancer cell lines without a Ras mutation; thus the activation of the Ras signaling pathway correlated positively with a higher level of p-ERK, p-AKT, and p-ELK1 ( Fig. 5A and Fig. S6A ). Furthermore, we found that growth of the lung cancer cells with an oncogenic Ras mutation seems to be more sensitive to inhibition by the MAPK inhibitor U0126 ( reliant on the hyperactive Ras-MAPK pathway. These data indicate that expression of MED23 is up-regulated specifically in lung cancer cell lines and that this up-regulation is closely associated with the Ras-mutation status of the cells. Considering that Med23 depletion selectively inhibited Ras-active cancer cell growth, it seems that MED23 is required for Ras addiction of lung cancers. On the other hand, the MED1 expression pattern was different from that of MED23, underlining the specific role of MED23 in Ras-active lung cancers (Fig. S7A) .
We also evaluated MED23 expression in human lung cancer tissues to determine whether the expression level of MED23 is correlated with lung carcinogenesis in vivo. The expression of MED23 was assessed using a tissue microarray with 188 NSCLC samples subjected to immunohistochemistry with a MED23 monoclonal antibody (Fig. 5B) . The clinical samples contained two different NSCLC subtypes: adenocarcinoma (n = 95) and squamous cell carcinoma (n = 93). A lung cancer section and the corresponding adjacent lung tissue were obtained from each Genes were sorted by fold change relative to si-Ctrl (P < 0.05). (E) GO analysis of the positive-overlap genes following Med23 or Elk1 knockdown. "Positive overlap" indicates a set of genes down-regulated after knockdown of Med23 or Elk1. Level 3 in biological process is shown in the graph, and all the top10 processes are significantly enriched (P < 0.001). Ranking is based on the number of changed genes. (F) Quantitative PCR confirmed the changes in the genes related to cell cycle or cell proliferation selected from the microarray analysis in E.
patient, allowing us to compare MED23 levels in normal versus neoplastic epithelium. In contrast to the adjacent normal tissues, most of the NSCLC samples from both adenocarcinomas and squamous cell carcinomas stained positive for MED23, which was clearly present in the epithelial cell nuclei. To quantify the differences between the normal and cancerous tissues objectively, a scoring system was implemented to analyze the immunohistochemical staining. Each section was scored using a staining index (33) composed of the intensity of the staining on a scale of 0-3 and the extent of the staining on a scale of 0-3. The final score of each sample was determined by multiplying the extent score by the intensity score; therefore, the final staining index ranged from 0 (no staining) to 9 (strong and extensive staining). Most of the adjacent normal tissue samples (96/ 188) were negative (0) for MED23, but nearly half of the NSCLC samples (91/188) exhibited a higher MED23 staining index (4-9). Indeed, 82.4% (155/188) of the cancerous tissues from the patients showed stronger staining than the surrounding normal epithelium (P < 0.0001, n = 188) (Fig. 5B and Fig. S7B ). Furthermore, MED23 expression levels did not differ between the adenocarcinoma and squamous cell carcinoma samples. These findings suggest that NSCLC tissues tend to have high MED23 expression and are consistent with our observations that MED23 is overexpressed in lung cancer cell lines.
Because MED23 expression levels were strongly associated with the Ras activity levels in lung cancer cell lines, we next asked if a similar correlation occurs in clinical NSCLC samples. Using the same NSCLC tissue array, consecutive sections of human lung cancers were stained for p-ERK and p-ELK1, because the levels of p-ELK1 and p-ERK are indicative of activated Ras signaling. Interestingly, we found that higher MED23 expression in the NSCLC samples correlated with higher p-ERK and p-ELK1 staining signals (Fig. 5C ). For statistical analysis the samples were divided into two groups (the higher half versus the lower half), based on their ERK and ELK1 phosphorylation levels. Higher levels of both p-ERK and p-ELK1 correlated with higher MED23 expression levels (P < 0.05) (Fig. 5D) . Taken together, these findings provide direct evidence that the elevated expression of MED23 in the clinical NSCLC samples is associated with activated Ras-MAPK signaling.
Because MED23 is required for the Ras transformation, and because the elevated MED23 expression in lung cancer cell lines and clinical samples correlated with hyperactive Ras activity, we wondered whether the expression of MED23 could be regulated by oncogenic Ras during Ras transformation. To exclude the possible change of MED23 expression during immortalization, we used primary MEFs to perform the transformation assay. In contrast to transforming immortalized MEFs, transforming primary MEFs requires multiple cooperating oncogenes (34) . Coexpression of Ras along with an immortalizing oncogene such as adenoviral E1A can easily induce a transformation phenotype in primary MEFs (35, 36) . Significantly, transformation of primary MEFs with the combination of Ras and E1A drives up both mRNA and protein levels of Med23 to a greater extent than seen with E1A alone or with E1A plus other oncogenes such as c-myc or T-antigen (Fig. S8 A and B) . Similarly, the activation of ERK and ELK1 also is highest in the Ras plus E1A transformation (Fig. S8A) . Interestingly, we observed that MED23 is not the only subunit that was up-regulated in the process of Ras transformation; many of the Mediator subunits examined with the available antibodies also were up-regulated during the Ras transformation (Fig. S8C) . The whole Mediator complex probably is up-regulated to meet the demand for faster proliferation; however, the MED23 subunit was specifically required for sensing and transducing the signal strength of the hyperactive Ras pathway. To demonstrate further the specificity of MED23 in Ras-driven tumorigenicity, we performed an important control experiment by knocking down another Mediator subunit, Med15. Although MED15 also showed elevated protein level during Ras transformation, Med15 knockdown failed to change the efficiency of Ras transformation or the growth rate of lung cancer cells with activated Ras activities (Fig. S9 A, C, and D) . Consistently, in contrast to MED23, MED15 protein levels show no correlation with the hyperactive Ras signaling in samples from lung cancer patients (Fig. S9B ). These observations further underscore the critical and specific role of MED23 in Ras signaling and oncogenesis.
Med23 Expression Is Associated with Prognosis of Patients with RasActive Lung Cancer. Given that Med23 is an important regulator of Ras-driven oncogenesis, patients bearing tumors with activated Ras would be expected to benefit from reductions in Med23 expression. To test this hypothesis, we analyzed whether the expression level of Med23 was associated with patient prognosis in a large cohort of lung cancer samples. In a previous study, a Ras-expression signature that included 766 genes first was derived from a microarray analysis of a small set of clinical lung tumor samples with known Ras mutation (37) . The signature genes were used as probes in an additional set of expression profiles from 442 human lung adenocarcinomas to stratify the samples as having positive, negative, or neutral Ras signatures (38) . Ultimately, researchers identified 143 tumors as having strong Ras mutant signatures (Ras + signature) and 116 as having WT Ras signatures (Ras − signature). Given the important role of Med23 in Ras-active lung cancer, we asked whether the expression level of Med23 in the clinical sample was associated with the patient's prognosis in a manner that was dependent on the tumor's Ras signature status. The lung cancer patients were separated into two groups based on the expression level of Med23 (higher half vs. lower half of Med23 expression). The higher group (designated by Med23 expression levels in the tumors that were higher than the median) was compared with the lower group (containing the rest of the cancer patients in the subset), using Kaplan-Meier analysis. Strikingly, we found that a lower level of Med23 expression was associated specifically with enhanced survival for the set of patients (143) who bore tumors with a positive Ras signature (P = 0.02); in contrast, the Med23 expression level had no predictive value for the set of patients (116) who bore tumors with a negative Ras signature (P = 0.84) (Fig. 6 A and B) . As a control, the expression of another Mediator subunit, Med15, did not associate with the prognoses of Ras-active lung cancer patients (Fig. S9E) . Taken together, these results suggest that the Med23 expression level is associated specifically with the prognoses of human lung cancer patients whose tumors contain activations in the Ras pathway. Therefore, Med23 expression level could be used to predict the clinical outcomes of patients with Ras-active lung cancer.
To explore further the clinical prognostic value of MED23, we generated a therapeutic mouse model to test the possible clinical applications of MED23 manipulation. First, an A549 cell line with a doxycycline (Dox)-induced RNAi knockdown of Med23 was established (Fig. 6C) . The cells then were injected s.c. into nude mice to form a xenograft tumor. Mice with tumor volume of at least 50 mm 3 were separated randomly into two groups. The treatment group was fed with water containing Dox (changed every 4 d) for 20 d to knock down Med23 (Fig. 6D) . The s.c. tumors of the Doxtreated animals were much smaller than those of the control group (without Dox treatment) (Fig. 6E) . Significantly, and as is consistent with the relationship between Med23 expression and clinical prognosis, the Dox-induced Med23 RNAi significantly increased the life span of the xenografted mice (P < 0.05) (Fig. 6F) . These data strongly support the idea that the attenuation of MED23 function is a restrictive force against Ras-mutated lung cancers. Therefore, MED23 may represent an attractive drug target for the clinical treatment of Ras-active lung cancers.
Discussion
In this work, we identified the Mediator subunit MED23 as an important regulator in lung cancer with oncogenic Ras signaling. By controlling a common set of cell-cycle-and cell-proliferationrelated genes, MED23 selectively regulates the proliferative potential and the tumorigenicity of lung cancer cells with an oncogenic Ras mutation. The depletion of Med23 specifically reduced the efficiency of transforming fibroblasts by Ras but not by c-Myc, underscoring the specific relationship between activated Ras and MED23 in oncogenesis. Furthermore, we observed that MED23 was up-regulated during Ras transformation and was overexpressed in the Ras-active lung cancer cell lines and in the lung tumors with hyperactive Ras activity. These data suggest that the elevation in MED23 expression could be caused by or result from Ras hyperactivity during lung carcinogenesis. Significantly, the expression level of Med23 could be useful in predicting the clinical outcomes of patients with hyperactive Ras signatures, suggesting that the Mediator MED23 subunit may serve as a diagnostic marker for individualized therapy. Overall, our data suggest that MED23 is required for the Ras addiction during lung carcinogenesis.
Our study on the transcription factor ELK1 may help explain the specific relationship between Ras signaling and Mediator MED23 in lung tumorigenesis. Through specific interaction with MED23 upon Ras or MAPK activation, the transcription factor ELK1 controls the expression of a gene set that is specifically involved in the regulation of Ras-active cancer-cell proliferation and Ras transformation. Interestingly, the phosphorylation levels of ELK1 also are elevated in both lung cancer cell lines and clinical lung cancer samples with active Ras activities and in the process of Ras transformation are strongly correlated with the expression levels of MED23. In contrast, the low Ras activity indicated by the low levels of p-ELK1 and p-ERK were correlated with low MED23 expression in the lung cancer cell lines without activated Ras mutation; consequently, growth control of these cells is not MED23 dependent. Therefore, the selective requirement for MED23 in lung cancer might depend on the signal strength of the Ras-MAPK pathway, as indicated by the level of ELK1 phosphorylation. Thus, ELK1 phosphorylation might be responsible for relaying the mutual dependence between Ras hyperactivity and overexpressed MED23 in lung cancer.
Aberrant transcriptional regulation that results in malignant gene-expression patterns often accompanies carcinogenesis (39, 40) . Many factors involved in transcriptional regulation are potential targets for cancer therapy, including p53 (41), HDAC (42), Myc (43), β-catenin (44), and elongation factor pTEFb (45), among others. Some of these targets are oncogenes that contribute directly to the malignant phenotype of certain types of tumors; others are nononcogenes that are important for maintaining or supporting the malignancy. The Mediator complex functions as an integrative hub for transmitting different signaling pathways through physical interactions between the various transcription factors and specific Mediator subunits. Recent studies (46) (47) (48) , including this one, have highlighted the specificity of different Mediator subunits in regulating distinct types of cancers through controlling specific signaling and gene programs. The current study demonstrated that, by channeling hyperactive Ras signaling, the MED23 subunit plays a highly specific role in regulating Ras-driven lung cancer. The protein level of Med23 was increased during Ras transformation and was up-regulated in lung cancer cell lines and in samples from patients who had lung cancer with hyperactive Ras activity. Because the Med23 mRNA level also was increased during Ras transformation, we examined the Med23 mRNA levels in distinct lung cancer cell lines and clinical samples. However, we failed to detect consistent differences in the levels of Med23 mRNA in normal and cancer tissues using a cDNA array and the Oncomine database (Fig. S10  A and C) . Moreover, no correlation with the Ras-mutation status in lung cancer cells lines was observed (Fig. S10B ). These observations suggested that the elevated MED23 protein level in samples from cancer patients might be caused by the protein stabilization resulting from hyperactive Ras signaling. On the other hand, we also noticed that MED23 is not the only subunit that was up-regulated in the process of Ras transformation; indeed, most of the Mediator subunits examined were up-regulated during Ras transformation. The increase of the Mediator complex probably is required by the enhanced cell growth, although MED23 subunit still was specifically required for sensing the signal strength of the hyperactive Ras pathway.
To address further whether the MED23 is specifically important in Ras-driven tumorigenesis, we compared the roles of several other Mediator components in carcinogenesis. Although MED15 also was increased during Ras transformation, Med15 RNAi did not inhibit the efficiency of Ras transformation or the growth rate of lung cancer cells with Ras mutations. Also, unlike MED23, MED15 protein levels did not correlate with the Ras activities in samples from lung cancer patients, and Med15 mRNA levels were not associated with the prognosis of patients with Rasactive lung cancer (Fig. S9) . Med1 is another well-studied subunit of the Mediator complex which can act as a key regulator of the nuclear hormone receptor signaling through binding with Androgen Receptor or Estrogen Receptor and plays an important and specific coregulatory role in prostate cancer and breast cancer cell proliferation and survival (46) . Moreover, the Mediator kinase subunit CDK8, which is important for the aberrant activation of the canonical WNT/β-catenin pathway, has been associated with a substantial percentage of colorectal cancers (47) . Most recently, Med12 was found to be mutated in a large percentage of uterine leiomyomas and might contribute to cancer progression (48) . These studies of other Mediator subunits in different types of cancer further highlight the specificity of MED23 in Ras-driven tumorigenesis.
Although Ras gene family members are mutated in ∼30% of human tumors, efforts to develop Ras-directed molecular therapeutics have proven challenging thus far (5, 6). An alternative approach is to search for inhibitors that bypass Ras to target the various Ras downstream signaling effectors, such as B-raf and MEK (10, 12) . Many new therapeutic agents currently are in clinical trials, and some of them have been shown to be efficacious in treating tumors with Ras mutations (49, 50) . However, resistance to these targeted therapies often occurs because the secondary mutations of the kinase abrogate drug binding or because other mutations occur along the pathway and reactivate the oncogenic signaling (51, 52) . MED23, which functions as a nuclear target of the Ras-MAPK kinase cascade and specifically controls a small set of genes, could be a target for drugs directed against aberrant Ras signal transduction and might be helpful in overcoming the prevalence of drug resistance. Because all the mutated oncogenes in Ras-MAPK pathway, such as EGFR, Ras, and Raf, share a common signal-transduction cascade, patients with mutations in any of these oncogenes might benefit from targeting MED23. Indeed, we observed that the loss of MED23 also could inhibit the growth of cancer cells with EGFR or B-raf mutations (Fig. S4 C and D) . Tumors often depend on the sustained expression and activity of a single aberrant initiating oncogene for the maintenance of the malignant phenotype and better cell survival (53) . This phenomenon, called "oncogene addiction," provides a rationale for molecular targeted therapy and offers potential therapeutic opportunities (54, 55) . Our study revealed that cancer cells harboring K-Ras mutations not only are addicted to oncogenic K-Ras but also rely on the entire Ras-MAPK pathway, including the downstream cofactor MED23, to maintain the addiction, suggesting that targeting MED23 might be used alone or in combination with other therapeutic agents to counteract the addictive Ras pathway. MED23, ELK1, or their interaction interface may represent multiple pharmaceutical targets in patients with Ras-mutated lung cancer, for whom currently there is no effective therapy.
Experimental Procedures
Plasmids and Materials. The Med23, Elk1, and Med15 RNAi sequences were determined using the Dharmacon siRNA designing tool and were cloned into pSiren-RetroQ (Clontech) (see SI Experimental Procedures for oligonucleotide sequences). pMXs-hc-MYC was obtained from Addgene. pWzl-Ha-RasV12 was a generous gift from Peiqing Sun (The Scripps Research Institute, San Diego). pLVUT-tTR-KRAB was a generous gift from Guoliang-Xu (Institute of Biochemistry and Cell Biology, Shanghai). Doxycycline used to induce Med23 RNAi was obtained from BD PharMingen. Cisplatin was from obtained SigmaAldrich. Human lung cancer samples were purchased from Shanghai Biochip Company Ltd. All animals were maintained and used in accordance with the guidelines of the Institutional Animal Care and Use Committee of the Shanghai Institutes for Biological Sciences. Retrovirus Infection. Stable cell lines to knock down or overexpress a gene of interest were established following the manufacturer's recommendations (Clontech) and have been described previously (21, 30) . Retroviruses were generated following the cotransfection of recombinant pSiren-RetroQ plasmids with pCL10A1 helper plasmid into 293T cells using Lipofectamine 2000 (Invitrogen). Tissue-culture supernatants containing retroviruses were harvested 48 h posttransfection and passed although a 0.45-μm filter. Cells were plated into six-well plates before retroviral infection. Virus-containing supernatants were supplemented with 20 μg/mL Polybrene (Sigma-Aldrich) and added to the cells for spin infection by centrifugation at 1,258 × g at 30°C for 1.5 h. Twenty-four hours after spin infection, MEFs were selected with 50 μg/mL puromycin or 500 μg/mL hygromycin (Sigma-Aldrich). A549 cells and the other lung cancer cells were selected with 5 μg/mL puromycin.
Cell-Proliferation Assay. After puromycin selection, si-Ctrl and si-Med23 cells were trypsinized and were seeded at 2 × 10 4 cells per well in 12-well plates. Cells were allowed to proliferate for an additional 6 d with medium changed after 3 d. Cell number was measured every day or 6 d after plating by a CYTORECON cell counter (GE Healthcare). Experiments were done in triplicate.
Growth Assays in Soft Agar. Soft agar growth assays were performed as described. For anchorage-independent growth, 2 × 10 4 A549 cells or transformed MEFs were resuspended in a medium containing 0.3% low-meltingpoint agarose and were plated onto a solidified bottom layer medium containing 0.5% agarose in six-well plates. The colonies that formed at 2 wk were stained with 1 mg/mL 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) for 6 h and were imaged.
Tumor-Formation Assays in Athymic Nude Mice. Five million A549 cells or one million transformed MEFs were injected s.c. into the flanks of 6-wk-old female nude mice in 100 μL of serum-free DMEM. Tumor growth was monitored for 7-10 wk for A549 cells and for 4-8 wk for transformed MEFs. The tumors were measured with a caliper every 4 d, and tumor volume was calculated as 0.5 × L × W × W. The tumors were weighed, processed, and imaged after surgical removal.
Microarray Analysis. The global expression of control, si-Med23, or si-Elk1 A549 cells was identified using Affymetrix Human Genome U133 plus 2.0 Arrays, and the data were extracted using RMA implemented in R. Present/absent calls were generated by MAS5 in R for human genome U133 plus 2.0 arrays; t tests were performed on predefined sample groups with n = 3. The log 2 foldchange was generated from control subtracting knockdown. The heat map was generated using z-scores across all the samples. The GO annotations were performed using GOminer (http://discover.nci.nih.gov/gominer/index.jsp).
Tissue Microarray and Immunohistochemistry. Three tissue microarray (TMA) chips containing a total of 188 pairs of tumors and matched adjacent tissues were obtained from Shanghai Biochip Company Ltd. Immunohistochemistry of the TMA Chips was carried out using primary antibodies against MED23 (BD), MED15 (Abcam), p-ERK (Santa Cruz), and p-ELK1 (Santa Cruz). Briefly, sections were dewaxed, hydrated, and washed. After neutralization of endogenous peroxidase and microwave antigen retrieval, slides were preincubated with blocking serum and then were incubated overnight with each antibody. Subsequently, the sections were serially rinsed, incubated with second antibodies, and treated with HRP-conjugated streptavidin. Reaction products were visualized with 3, 3-diaminobenzidine tetrahydrochloride and counterstained with hematoxylin. For each antibody, all tissue microarray staining was done in a single experiment, including negative staining controls.
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SI Experimental Procedures
Sequences for siRNA Oligonucleotides. The sequences for small interfering RNA (siRNA) were si-Ctrl: 5′-gtgcgctgctggtgccaac-3′ si-Med23 A: 5′-aggcaaagaagttgggaat-3′ si-Med23 B: 5′-tgaagcccaggtttgttat-3′ si-Med23 C: 5′-ggaacaaactgtatggctt-3′ si-Elk1 A: 5′-agttggtggatgcagagga-3′ si-Elk1 B: 5′-gaatcacacccttggaata-3′ si-Elk1 C: 5′-ggatgtgagtagaagagtt-3′ si-Med15: 5′-acacagaggacataggaaa-3′
Primer Sequences Used for Real-Time PCR Analysis. The following primer sequences were used for real-time PCR analysis.
Egr1 forward: 5′-tgaccgcagagtcttttcct-3′; reverse: 5′-tgggttggtcatgctcacta-3′ Egr2 forward: 5′-gagataccatcccaggctca-3′; reverse: 5′-ctccaccgggtagatgttgt-3′ Ier2 forward: 5′-gacacacggacacaatcagc-3′; reverse: 5′-aacaaaacgccaggtagacg-3′ c-fos forward: 5′-ggaattaacctggtgctgga-3′; reverse: 5′-accacctcaacaatgcatga-3′ GAPDH forward: 5′-cgaccactttgtcaagctca-3′; reverse: 5′-aggggagattcagtgtggtg-3′ β-actin forward: 5′-caccccgtgctgctgac-3; reverse: 5′-ccagaggcgtacagggatag-3′ EREG forward: 5′-ccaaggacggaaaatgctta-3′; reverse: 5′-aaaattagctgggcatggtg-3′ FGF2 forward: 5′-ggtgaaaccccgtctctaca-3′; reverse: 5′-tctgttgcctaggctggact-3′ RIF1 forward: 5′-tttccctctgaagtggttgg-3′; reverse: 5′-ccacctcactgcctcttctc-3′ CDK6 forward: 5′-tgcacagtgtcacgaacaga-3′; reverse: 5′-acctcggagaagctgaaaca-3′
BCAT1 forward: 5′-aagaggtggtggggactttt-3′; reverse: 5′-tccactgcatagtgcaaagc-3′ CENPF forward: 5′-gtggcaacagaagctgacaa-3′; reverse: 5′-tcttctgtgtcgatgccaag-3′ DBF4 forward: 5′-cagtaagagatgggggcaaa-3′; reverse: 5′-cgccatctgtttggattctt-3′ TTK forward: 5′-gaacatgccaccacaagatg-3′; reverse: 5′-ccaaatctcggcattctgat-3′ NUF2 forward: 5′-gaaaaacttgccacagcaca-3′; reverse: 5′-tccctttcagcagcatcttt-3′ 
